Skip to content

Haemonetics HAE Deferred Revenue

Deferred Revenue at other companies

LivaNova logo
LivaNovaLIVN
$16.2M+41.5%
ICU Medical logo
ICU MedicalICUI
$60.66M
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC
$2.15B+14.0%
Medtronic logo
MedtronicMDT
Danaher logo
DanaherDHR
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$346.4M+4.8%
Gross profit$198.2M+2.7%
Operating income$67.4M+14.2%
Net income$44.7M+19.3%
EPS (diluted)$0.95+28.4%

Balance sheet

See full
Cash & equivalents$245.4M-20.0%
Total debt$1.3B-0.7%
Total equity$796.3M-3.0%
Total assets$2.4B-2.2%

Cash flow

See full
Operating cash flow$70.9M-39.1%
CapEx$17.7M+12.9%
Free cash flow$53.3M-47.2%

Valuation

See full
Market cap$3.31B-18.0%

Profitability

See full
Gross margin59%+4.0pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin19.5%+9.1pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.6×0.0×
Current ratio+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligation.

The official record: Haemonetics’s 10-Q, filed February 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Haemonetics's deferred revenue?
Haemonetics (HAE) reported deferred revenue of $36.6M in Q4 2025.
How has Haemonetics's deferred revenue changed year-over-year?
Haemonetics's deferred revenue increased by 9.9% year-over-year, from $33.3M to $36.6M.
What does deferred revenue mean?
Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.